Cardiovascular risk factors in patients on long-term treatment with nevirapine- or efavirenz-based regimens

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 4, 2011, Pages 896-900

  Maggi, Paolo ^a   Bellacosa, Chiara ^a   Carito, Valentina ^a   Perilli, Francesco ^a   Lillo, Antonio ^a   Volpe, Anna ^a   Trillo, Giovanna ^a   Angiletta, Domenico ^a   Regina, Guido ^a   Angarano, Gioacchino ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Antiretroviral therapy; Colour Doppler ultrasonography; Non nucleoside reverse transcriptase inhibitors; Subclinical carotid lesions

Indexed keywords

ABACAVIR; CHOLESTEROL; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEVIRAPINE; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL; ZIDOVUDINE;

ADULT; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DOPPLER ECHOGRAPHY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HYPERTENSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY;

ADULT; AGED; ANTI-HIV AGENTS; BENZOXAZINES; BLOOD CHEMICAL ANALYSIS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CAROTID ARTERIES; FEMALE; HUMANS; LIPIDS; MALE; MIDDLE AGED; NEVIRAPINE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; ULTRASONOGRAPHY, DOPPLER, COLOR;

EID: 79952803065     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq507     Document Type: Article

References (21)

1. The DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723-35.
2. The DAD Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371: 1417-26.
3. Lang S, Mary-Krause M, Cotte L et al. Impact of specific NRTI and PI exposure on the risk of myocardial infarction: a case-control study nested within FHDH ANRS CO4. In: Abstracts of the Sixteenth Conference on Retroviruses and Opportunistic Infections, Montreal, 2009. Abstract 43LB. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
4. Worm SW, Sabin C, Weber R et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201: 318-30.
5. Maggi P, Lillo A, Perilli F et al. on behalf of the PREVALEAT group. Colour-Doppler ultrasonography of carotid vessels in patients treated with antiretroviral therapy: a comparative study. AIDS 2004; 18: 1023-8.
6. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
7. de Bray JM, Glatt B. Quantification of atheromatous stenosis in the extracranial internal carotid artery. Cerebrovasc Dis 1995; 5: 414-26.
8. Mitchell DG. Color Doppler imaging: principles, limitations, and artifacts. Radiology 1990; 177: 1-10.
9. Ricotta JJ, Bryan FA, Bond MG et al. Multicenter validation study of real-time (B-mode) ultrasound, arteriography, and pathologic examination. J Vasc Surg 1987; 6: 512-20.
10. Steinke W, Meairs S, Ries S et al. Sonographic assessment of carotid artery stenosis. Comparison of power Doppler imaging and color Doppler flow imaging. Stroke 1996; 27: 91-4.
11. Triant VA, Lee H, Hadigan C et al. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92: 2506-12.
12. Raffi F, Bonnet B, Ferré V et al. Substitution of a nonnucleoside reverse transcriptase inhibitor for a protease inhibitor in the treatment of patients with undetectable plasma human immunodeficiency virus type 1 RNA. Clin Infect Dis 2000; 31: 1274-8.
13. van der Valk M, Kastelein JJP, Murphy RL et al. Nevirapine-containing antiviral therapy in HIV-1-infected patients results in an anti-atherogenic lipid profile. AIDS 2001; 15: 2407-14.
14. Gil P, Gorgolas M, Estrada V et al. Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected patients with undetectable viral load. Clin Infect Dis 2004; 39: 1024-9.
15. Negredo E, Cruz L, Paredes R et al. Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clin Infect Dis 2002; 34: 504-10.
16. Martinez E, Arnaiz JA, Podzamczer D et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.NEnglJMed2003; 349: 1036-46.
17. van Leth F, Phanuphak P, Stroes E et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 2004; 1: e19.
18. Greenland P, Smith SC, Grundy SM. Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests. Circulation 2001; 104: 1863-7.
19. Smith SC Jr, Amsterdam E, Balady GJ et al. Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: tests for silent and inducible ischemia: Writing Group II. Circulation 2000; 101: E12-6.
20. O'Leary DH, Polak JF, Kronmal RA et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340: 14-22.
21. O'Leary DH, Polak JF, Wolfson SK Jr et al. Use of sonography to evaluate carotid atherosclerosis in the elderly. The Cardiovascular Health Study. CHS Collaborative Research Group. Stroke 1991; 22: 1155-63.